Document is current
Any future updates will be listed below
-
Authors
Deka, Kamalakshi
Carter, Jean-Michel https://orcid.org/0000-0001-7932-2368
Bahai, Akash
Ang, Daniel Aron https://orcid.org/0000-0002-5868-5458
Sim, Nicholas https://orcid.org/0000-0001-5710-3762
Chong, Hooi Yan
Lee, Guan Hwee Bernard
Tan, Suet Mien https://orcid.org/0000-0003-2371-8739
Chng, Wee Joo https://orcid.org/0000-0003-2578-8335
Kappei, Dennis https://orcid.org/0000-0002-3582-2253
Li, Yinghui https://orcid.org/0000-0002-9023-9466
-
Funding
Funding for this research was provided by:
MOH | National Medical Research Council (MOH-001710)
Ministry of Education - Singapore (RT18/23, RG33/20)
National Research Foundation Singapore (NRF-NRFF2018-04)
- License Information
-
More Information
Article History
Received: 17 October 2024
Accepted: 14 August 2025
First Online: 1 September 2025
Competing interests
: Yinghui Li and Kamalakshi Deka are co-inventors of a provisional patent application - 10202501192X (Title: Design of antisense oligonucleotides targeting EZH2 activity as a new treatment modality for drug resistant cancers) for the in-silico docking models of PLUM-EZH2 complex, design and functional validation of steric ASOs described in this paper. The other authors declare no competing interests.
